Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Baxter Invests $100M to Expand Sterile Fill/Finish Mfg. Facility in Germany | Contract Pharma

What are you searching for?

Sign in
Breaking News

Baxter Invests $100M to Expand Sterile Fill/Finish Mfg. Facility in Germany

Adds syringe filling line, additional liquid and lyophilized vial capacity, and expands manufacturing footprint.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Baxter International Inc., a global provider of sterile medication production and delivery, is investing approximately $100 million to expand its sterile fill/finish manufacturing facility in Halle/Westfalen, Germany. This facility is operated by Baxter’s BioPharma Solutions (BPS), a business unit that specializes in the development and contract manufacturing of drug product for parenteral (injectable) pharmaceuticals. Construction is expected to begin in 2022 and be completed in 2024.
 
The strategic investment will expand the BPS manufacturing footprint and add state-of-the-art equipment designed to help products achieve stability and improved shelf life through lyophilization. Construction will also add an aseptic syringe filling line, enabling BPS to meet the growing demand for this delivery platform in both Europe and the U.S. Pre-filled syringes can enhance efficiency and ease-of-use for clinicians and have potential to minimize microbial contamination and reduce medication dosing errors.
 
“Baxter’s manufacturing site in Halle/Westfalen is one of the most advanced facilities in our global network and has seen significant growth over the last several years,” said Marie Keeley, general manager, Baxter BioPharma Solutions. “By making this investment, we are building on recent expansions to help ensure this facility can serve our partners at the highest level now and well into the future.”
 
Baxter’s Halle/Westfalen site is recognized as a world-class manufacturer of cytotoxic and highly potent drugs, offering dedicated clinical development through commercial production with integrated technologies and services, including barrier technology that helps maintain a high level of containment when manufacturing sensitive and sophisticated drugs, and broad sterile manufacturing capabilities The Halle/Westfalen facility is currently engaged in multiple collaborations to provide sterile manufacturing services for COVID-19 vaccines.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics